Bionano Genomics (NASDAQ:BNGO) Cut to Neutral at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH cut shares of Bionano Genomics (NASDAQ:BNGO) from a buy rating to a neutral rating in a research report released on Friday morning, Marketbeat reports.

BNGO has been the subject of a number of other research reports. Scotiabank reiterated a “sector perform” rating and set a $1.00 target price (down previously from $6.00) on shares of Bionano Genomics in a report on Wednesday, August 28th. BTIG Research downgraded shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Tuesday, September 10th.

Bionano Genomics Price Performance

Shares of Bionano Genomics stock opened at $0.23 on Friday. The business’s fifty day moving average price is $0.36 and its 200 day moving average price is $0.59. Bionano Genomics has a twelve month low of $0.22 and a twelve month high of $2.27. The company has a current ratio of 1.63, a quick ratio of 1.11 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $19.61 million, a P/E ratio of -0.10 and a beta of 2.37.

Institutional Investors Weigh In On Bionano Genomics

Institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in Bionano Genomics during the 1st quarter worth approximately $36,000. Price T Rowe Associates Inc. MD lifted its position in shares of Bionano Genomics by 123.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock worth $79,000 after purchasing an additional 38,900 shares in the last quarter. Carret Asset Management LLC boosted its stake in shares of Bionano Genomics by 89.0% in the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock valued at $39,000 after purchasing an additional 40,055 shares during the period. GSA Capital Partners LLP acquired a new stake in Bionano Genomics during the 3rd quarter valued at $46,000. Finally, Cetera Advisors LLC purchased a new stake in Bionano Genomics during the 1st quarter worth $163,000. Hedge funds and other institutional investors own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.